Considering the advances in AI technology and intellectual property law, how do these recent developments shape the outlook of AI patentability?
Starting January 1, 2026, all archived content will be exclusively available through a subscription to Law.com NewsVault.
For information about Law.com NewsVault, please email [email protected] or click here to learn more.
NOT FOR REPRINT
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
A three-judge panel, in an opinion written by Circuit Judge Barrington Parker, said that Armistice Capital’s sales of Vaxart Inc. stock were exempt from restrictions on so-called short-swing trades as Armistice had purchased the securities directly from Vaxart with the approval of its board of directors.
David Siffert, legal director at S.T.O.P., discusses 23andMe’s possible bankruptcy along with the potential legal fallout and the privacy threat it poses to our genetic data.
The developments follow the U.S. Supreme Court's 5-4 ruling on June 27 that rejected a nationwide settlement.
This issue of the Bankruptcy Update column focuses on the recent biotech industry bankruptcy cases of Zymergen and Humanigen.
A discussion of synthetic biology and its intersection with privacy/cybersecurity laws.
